Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102199633B reveals a green yeast-based route for high-purity chiral esters, offering significant cost and supply chain advantages for pharma.
Novel Ru-catalyzed route for Anacetrapib intermediate ensures high purity and scalable production for global pharmaceutical supply chains and cost efficiency.
Patent CN114350631B reveals a novel NADH-dependent enzyme mutant for L-glufosinate synthesis, offering significant cost reduction and supply chain stability for agrochemical manufacturing.
Patent CN114908129B reveals a novel dehydrogenase mutant for high-purity (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering significant cost and supply chain advantages.
Novel organoaluminum-catalyzed reduction method for high-purity Nebivolol intermediates, offering superior chiral selectivity and simplified processing for pharmaceutical supply chains.
Patent CN104263768A reveals Candida biocatalysis for chiral esters. Offers high yield and ee. Reliable supply chain and cost reduction for pharmaceutical manufacturing.
Patent CN102382780A reveals a novel Microbacterium oxydans strain for high-purity chiral alcohol production, offering significant cost reduction and supply chain stability for global API manufacturers.
Novel decarboxylation condensation and asymmetric reduction method enhances purity and reduces costs for sitagliptin manufacturing supply chains.
Patent CN101993828B details a dual-enzyme system for (S)-phenyl glycol. Achieve 100% e.e. and reduced manufacturing costs with scalable biocatalysis.
Novel CBS-catalyzed route for Tacalcitol. Avoids UV and sodium amalgam. Scalable, safe, cost-effective manufacturing for pharma supply chains.
Novel KmAKR mutants enable high-yield enzymatic synthesis of rosuvastatin side chains, offering superior stability and cost-effective manufacturing solutions.
Patent CN1439643A details a stable spirocyclic bisphosphine ligand offering 99.5% ee and high turnover numbers for efficient pharmaceutical intermediate manufacturing.
Patent CN103255183B details enzymatic synthesis of S-CHBE. High purity and yield offer supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN102605011B details a novel KRED102-catalyzed route for statin intermediates, offering high-purity chiral building blocks with simplified aqueous processing and reduced manufacturing costs.
Patent CN102978249A details a single-enzyme biocatalytic route for statin intermediates. Achieve >99% ee with simplified workup and reduced manufacturing costs.
Patent CN102925501A details a high-efficiency enzymatic route for statin intermediates, offering superior purity and scalable manufacturing capabilities for global supply chains.
Patent CN103642747A details a high-efficiency recombinant E. coli method for chiral alcohol production, offering superior ee >99% and cost-effective cofactor regeneration for pharma supply chains.
Patent CN102154377B reveals ScCR enzyme for asymmetric reduction. Enables cost-effective manufacturing of pharmaceutical intermediates with self-regenerating cofactors.
Patent CN112458143B reveals a novel whole-cell catalytic route for Ezetimibe intermediates. Discover how this green biocatalysis technology reduces costs and ensures supply chain stability.
Patent CN104846025A details enzymatic synthesis of chiral intermediates. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.